The 2016 Annual Meeting of the European Society of Medical Oncology (ESMO) was characterized by an abundance of presentations of novel and potentially practice-changing clinical trial results never seen before at a European cancer conference. This clearly underlines the importance of this meeting among the plethora of other oncology congresses. Within this huge amount of data, two main trends were observed: Immunotherapy with immune checkpoint modulators is still at the very center of scientific interest with further treatment individualization being a second main emphasis.

This short review reflects the personal highlights of three experts in medical oncology in their respective fields of expertise.

Dr. Dediu: {#FPar1}
==========

My personal highlights of ESMO 2016:

Paradigm-changing data: Ipilimumab was superior to placebo \[[@CR1]\] as adjuvant therapy of malignant melanoma while pembrolizumab was better than chemotherapy as first-line therapy in non-small-cell lung cancer (NSCLC) with ≥50% PD-L1 expression without *EGFR* mutation or *ALK* translocation \[[@CR2]\], for both in terms of overall survival.Data-confirming important previous advances: Addition of the CDK4/6 inhibitor ribociclib to the aromatase-inhibitor (AI) letrozole as first-line therapy in estrogen-receptor (ER)-positive HER2-negative patients with advanced breast cancer yielded superior progression-free survival (PFS) data over endocrine therapy alone \[[@CR3]\]. Niraparib, a novel PARP inhibitor, prolonged PFS when used as maintenance therapy in platinum-sensitive ovarian cancer irrespective of the presence or absence of *BRCA* germline mutations \[[@CR4]\]. Atezolizumab, a monoclonal antibody targeting PD-L1, was successfully tested as second- and third-line therapy in NSCLC \[[@CR5]\] while other immune checkpoint modulators such as pembrolizumab \[[@CR6]\] and nivolumab \[[@CR7]\] showed promising results in advanced urothelial cancer.Promising data that should await further confirmation before being translated into the clinical routine setting: Sunitinib was superior to placebo as adjuvant treatment of renal cell cancer (RCC) \[[@CR8]\]; furthermore, cabozantinib was superior to sunitinib as first-line therapy of metastatic RCC \[[@CR9]\]. Finally, the anti-estrogen fulvestrant was superior to the AI anastrozole as first-line therapy in ER-positive metastatic breast cancer although this benefit was apparently restricted to patients with visceral metastases \[[@CR10]\].

Dr. Gerger: {#FPar2}
===========

Colorectal cancer "sidedness":

Colorectal cancer is a heterogeneous disease. In contrast to the left-sided colon, which derives from the embryonic hindgut, the right-sided colon originates from the midgut.

Primary tumors arising from different regions of the colon are molecularly and clinically distinct. Left-sided tumors more frequently possess a molecular profile of an EGFR inhibitor-sensitive phenotype, which is reflected in *EGFR/ERB-B2* and epiregulin amplification; conversely, right-sided tumors show more frequently *BRAF* mutations and microsatellite instability. These molecular differences manifest in different clinical behavior, with right-sided tumors harboring a worse prognosis. At this year's ESMO conference in Copenhagen, the predictive value of colon cancer sidedness was comprehensively discussed including retrospective analyses of the anti-VEGF versus anti-EGFR head-to-head trials FIRE-3, PEAK, and CALGB80405 \[[@CR11]\]. In summary, in first-line therapy of patients with left-sided *RAS* wild-type tumors, a combination therapy consisting of an EGFR antibody with chemotherapy is recommended. In patients with right-sided *RAS* wild-type tumors, there is presently no proven benefit of an EGFR antibody compared with bevacizumab. Therefore, a bevacizumab plus chemotherapy combination is recommended.

Dr. Zojer: {#FPar3}
==========

My personal highlights of ESMO 2016:

Apart from the seminal results of the KEYNOTE-024 and CheckMate-026 lung cancer trials, the following two presentations seem to have practice-changing impact: Mirza et al. \[[@CR4]\] reported results from a randomized double-blind phase 3 trial of maintenance therapy with the PARP inhibitor niraparib versus placebo (2:1) in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Overall, 553 patients were enrolled after response to platinum chemotherapy, 203 with a germline *BRCA* mutation and 350 patients without such a mutation. Interestingly, niraparib maintenance improved outcome in terms of PFS not only in the patient cohort with *BRCA* mutation (PFS, 21.0 months versus 5.5 months; *p* \< 0.0001) but also in the *BRCA* wild-type subset (PFS, 9.3 months versus 3.9 months, *p* \< 0.0001). Although overall outcome was better in the mutant subset, these results seem to indicate that PARP inhibition is an effective treatment modality for ovarian cancer independent of germline *BRCA* mutation status. Important results were also reported on the adjuvant treatment of stage III melanoma. Eggermont et al. \[[@CR1]\] showed that ipilimumab not only prolonged relapse-free survival in this setting, but also led to an improvement in terms of overall survival compared with placebo (5-year overall survival 65.4% versus 54.4%; *p* = 0.001; EORTC 18071 trial).
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